Matches in SemOpenAlex for { <https://semopenalex.org/work/W1840268462> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W1840268462 endingPage "71" @default.
- W1840268462 startingPage "71" @default.
- W1840268462 abstract "71 Background: Androgen receptor splice variants (ARvs) are upregulated in response to castration, and can activate transcription in the absence of ligand. Recent evidence indicates that CTC ARv7 expression is an accurate predictor of absence of response to abiraterone and enzalutamide, providing strong clinical support for ARv7 upregulation as potential overarching mechanism of castration resistance. There is however limited data regarding the expression of ARv7 in clinically localized prostate cancer (CaP), and it is unknown if expression in the primary tumor is similarly predictive. We were therefore interested to determine the expression of ARv7 in high-risk disease, and correlate this with response to an abiraterone-containing castrating regimen. Methods: We performed an open label non-randomized Phase II neoadjuvant study of ‘supercastration’ in men with high-risk clinically localized CaP using an optimal 2-stage design (ACTRN12612000772842). Treatment consisted of degarelix 240/80mg q 1/12, abiraterone 1000mg OD, bicalutamide 50mg OD and prednisolone 5mg OD for 24 weeks. The primary endpoints were safety/tolerability and pT0 response rate. ARv7 expression was determined by immunohistochemistry and qRT-PCR in both pre- and post treatment tumor specimens, and correlated with pathological response. Fresh specimens from resistant tumors are currently being profiled by RNA-seq. Results: 17 patients were recruited to the study. The combination treatment was well tolerated, with hot flushes and fatigue being the most commonly reported side effects, and all patients completed six months of treatment. Six patients with asymptomatic elevation of liver transaminases required Abiraterone dose reductions, and there were no unexpected toxicities. 16 patients proceeded to prostatectomy, and a pT0 response observed in one patient, with minimal residual disease present in a further three patients. ARv7 expression was uniformly present in all pre-treatment specimens, and neither level nor localization of expression predicted tumor response. Conclusions: ARv7 expression in primary CaP does not predict response to abiraterone-based castration. Clinical trial information: ACTRN12612000772842." @default.
- W1840268462 created "2016-06-24" @default.
- W1840268462 creator A5000291176 @default.
- W1840268462 creator A5013449537 @default.
- W1840268462 creator A5016853227 @default.
- W1840268462 creator A5034617895 @default.
- W1840268462 creator A5035552175 @default.
- W1840268462 creator A5035778911 @default.
- W1840268462 creator A5040108654 @default.
- W1840268462 creator A5046475317 @default.
- W1840268462 creator A5049360066 @default.
- W1840268462 creator A5062270975 @default.
- W1840268462 creator A5065533194 @default.
- W1840268462 creator A5073302447 @default.
- W1840268462 creator A5080627838 @default.
- W1840268462 creator A5086680226 @default.
- W1840268462 date "2015-03-01" @default.
- W1840268462 modified "2023-10-02" @default.
- W1840268462 title "The predictive value of ARv7 expression in localized prostate caner treated with abiraterone, degarelix, and bicalutamide." @default.
- W1840268462 doi "https://doi.org/10.1200/jco.2015.33.7_suppl.71" @default.
- W1840268462 hasPublicationYear "2015" @default.
- W1840268462 type Work @default.
- W1840268462 sameAs 1840268462 @default.
- W1840268462 citedByCount "5" @default.
- W1840268462 countsByYear W18402684622018 @default.
- W1840268462 countsByYear W18402684622021 @default.
- W1840268462 countsByYear W18402684622023 @default.
- W1840268462 crossrefType "journal-article" @default.
- W1840268462 hasAuthorship W1840268462A5000291176 @default.
- W1840268462 hasAuthorship W1840268462A5013449537 @default.
- W1840268462 hasAuthorship W1840268462A5016853227 @default.
- W1840268462 hasAuthorship W1840268462A5034617895 @default.
- W1840268462 hasAuthorship W1840268462A5035552175 @default.
- W1840268462 hasAuthorship W1840268462A5035778911 @default.
- W1840268462 hasAuthorship W1840268462A5040108654 @default.
- W1840268462 hasAuthorship W1840268462A5046475317 @default.
- W1840268462 hasAuthorship W1840268462A5049360066 @default.
- W1840268462 hasAuthorship W1840268462A5062270975 @default.
- W1840268462 hasAuthorship W1840268462A5065533194 @default.
- W1840268462 hasAuthorship W1840268462A5073302447 @default.
- W1840268462 hasAuthorship W1840268462A5080627838 @default.
- W1840268462 hasAuthorship W1840268462A5086680226 @default.
- W1840268462 hasConcept C121608353 @default.
- W1840268462 hasConcept C126322002 @default.
- W1840268462 hasConcept C143998085 @default.
- W1840268462 hasConcept C197934379 @default.
- W1840268462 hasConcept C203092338 @default.
- W1840268462 hasConcept C2775832370 @default.
- W1840268462 hasConcept C2776551883 @default.
- W1840268462 hasConcept C2777899217 @default.
- W1840268462 hasConcept C2778375690 @default.
- W1840268462 hasConcept C2780192828 @default.
- W1840268462 hasConcept C2780962315 @default.
- W1840268462 hasConcept C502942594 @default.
- W1840268462 hasConcept C535046627 @default.
- W1840268462 hasConcept C61367390 @default.
- W1840268462 hasConcept C71924100 @default.
- W1840268462 hasConceptScore W1840268462C121608353 @default.
- W1840268462 hasConceptScore W1840268462C126322002 @default.
- W1840268462 hasConceptScore W1840268462C143998085 @default.
- W1840268462 hasConceptScore W1840268462C197934379 @default.
- W1840268462 hasConceptScore W1840268462C203092338 @default.
- W1840268462 hasConceptScore W1840268462C2775832370 @default.
- W1840268462 hasConceptScore W1840268462C2776551883 @default.
- W1840268462 hasConceptScore W1840268462C2777899217 @default.
- W1840268462 hasConceptScore W1840268462C2778375690 @default.
- W1840268462 hasConceptScore W1840268462C2780192828 @default.
- W1840268462 hasConceptScore W1840268462C2780962315 @default.
- W1840268462 hasConceptScore W1840268462C502942594 @default.
- W1840268462 hasConceptScore W1840268462C535046627 @default.
- W1840268462 hasConceptScore W1840268462C61367390 @default.
- W1840268462 hasConceptScore W1840268462C71924100 @default.
- W1840268462 hasIssue "7_suppl" @default.
- W1840268462 hasLocation W18402684621 @default.
- W1840268462 hasOpenAccess W1840268462 @default.
- W1840268462 hasPrimaryLocation W18402684621 @default.
- W1840268462 hasRelatedWork W1902440608 @default.
- W1840268462 hasRelatedWork W2050595427 @default.
- W1840268462 hasRelatedWork W2309274182 @default.
- W1840268462 hasRelatedWork W2488918559 @default.
- W1840268462 hasRelatedWork W2561387856 @default.
- W1840268462 hasRelatedWork W2595758682 @default.
- W1840268462 hasRelatedWork W2805553258 @default.
- W1840268462 hasRelatedWork W3161788990 @default.
- W1840268462 hasRelatedWork W3202359850 @default.
- W1840268462 hasRelatedWork W4229076799 @default.
- W1840268462 hasVolume "33" @default.
- W1840268462 isParatext "false" @default.
- W1840268462 isRetracted "false" @default.
- W1840268462 magId "1840268462" @default.
- W1840268462 workType "article" @default.